Abstract Number: OC 33.3
Meeting: ISTH 2021 Congress
Background: Preeclampsia (PE) is a systemic multifactorial disease that occurs from the twentieth week of gestation in previously normotensive women. The imbalance between pro and antiangiogenic factors and inflammation have been considered crucial for the development of PE. The highly specific interaction of Fibroblast Growth Factor 2 (FGF2), an important pro-angiogenic factor, with the acute phase protein Pentraxin 3 (PTX3) prevents the engagement of FGF2 to its specific receptors and impair their biological activities, including angiogenesis. Some studies report the increased levels of PTX3 and FGF2 in PE.
Aims: To compare the levels of PTX3 and FGF2 in plasma of normotensive and pre-eclamptic pregnant women and to evaluate the levels of these molecules as potential biomarkers of early and late PE.
Methods: This is a case-control study (Ethics Committee approval ETIC0618.0.203.000-10) that measured by sandwich ELISA, PTX3 and FGF2 plasma levels at the final third trimester of pregnancy from non-pregnant women (n = 19), normotensive pregnant women (n = 42) pregnant women with PE (43).
Shows patient’s clinical characteristics
Results: PTX3 and FGF2 levels are significantly higher (p <0.05) in pregnant women with PE than in normotensive pregnant women (NT) in the same period (fig 1). The higher levels of PTX3 in PE do not allow discrimination between early and late PE, however the concentration of FGF2 in the early PE was on average 2 times higher than those observed in both the plasma of NT and with late PE (fig 2). Pearson correlation coefficient indicates that PTX3 and FGF2 concentrations behave independently, and no correlation was found between the levels of these factors in PE.
Plasma concentration of FGF2 and PTX3 during normal pregnancy and in preeclampsia (Fig. 1) and in early and late PE (Fig. 2)
Conclusions: FGF2 and PTX3 plasma concentrations are found elevated in PE and the increased levels of FGF2 correlates with the early PE, the most severe form of the disease, highlighting its potential as a marker of severity.
Financial support: CAPES, CNPq and FAPEMIG.
To cite this abstract in AMA style:
Santiago de Oliveira F, de Oliveira Perucci L, Maria Sant'Ana Dusse L, Nessralla Alpoim P, Abalen Martins Dias A. Increased Plasma Concentration of Pentraxin 3 and Fibroblast Growth Factor 2 in Preeclampsia [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/increased-plasma-concentration-of-pentraxin-3-and-fibroblast-growth-factor-2-in-preeclampsia/. Accessed August 19, 2022.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/increased-plasma-concentration-of-pentraxin-3-and-fibroblast-growth-factor-2-in-preeclampsia/